Business Context and Reporting Period
Company: Inogen, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2013
Business Overview: Inogen is a medical technology company developing, manufacturing, and marketing portable oxygen concentrators (Inogen One systems) for patients with chronic respiratory conditions. The company utilizes a direct-to-consumer strategy, marketing directly to patients and billing Medicare or insurance providers, distinguishing it from competitors who rely on home medical equipment distributors. In 2013, the company was the leading worldwide manufacturer of portable oxygen concentrators by dollar volume.
Key Financial Metrics
| Metric | 2013 | 2012 |
|---|---|---|
| Total Revenue | $75.4 million | $48.6 million |
| Gross Profit | $39.0 million | $23.9 million |
| Gross Margin | 51.7% | 49.3% |
| Net Income (GAAP) | $25.4 million | $0.6 million |
| Adjusted Net Income | $3.6 million | $0.6 million |
| Adjusted EBITDA | $13.4 million | $5.9 million |
| Cash and Cash Equivalents | $13.5 million | $15.1 million |
| Total Debt Outstanding | $10.6 million | $8.9 million |
| Working Capital | $13.2 million | $12.9 million |
Note: The 2013 GAAP Net Income includes a one-time tax benefit of approximately $21.8 million from the reversal of a deferred tax valuation allowance. Adjusted Net Income excludes this benefit.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 55.3% to $75.4 million, driven by a 56.6% increase in sales revenue and a 53.7% increase in rental revenue. Rental revenue now represents 41% of total revenue, up from 35.8% in 2011.
- Profitability: The company transitioned from a net loss of $2.6 million in 2009 to net income of $25.4 million in 2013. Operating income improved from $0.8 million in 2012 to $4.5 million in 2013.
- Margin Expansion: Gross margin improved to 51.7% from 49.3% due to a favorable sales mix shift toward higher-margin direct-to-consumer sales, improved system reliability, and reduced material costs.
- Customer Base: The rental patient base grew from over 13,500 in 2012 to over 21,300 in 2013.
Guidance, Outlook, and Risks
- Outlook: Management expects continued growth in sales and rental revenue through expanded direct-to-consumer marketing, international distribution, and new product launches (including the Inogen At Home stationary concentrator expected in 2014).
- Medicare Competitive Bidding: A significant risk factor is the Medicare competitive bidding program. In 2013, the company was excluded from contracts in approximately 7% of the Medicare market (17 areas), which is expected to have an adverse impact on rental revenue. However, the company retains access to approximately 90% of the Medicare market.
- Reimbursement Rates: Reimbursement rates in competitive bidding areas are significantly lower (58-69% of standard allowables) than in non-competitive areas. Private payor rates are expected to reset in accordance with Medicare competitive bidding levels.
- Internal Controls: The company previously identified material weaknesses in internal controls over financial reporting (related to staffing, revenue recognition, and warranty accounting) in 2011 and 2012. Management believes these were remediated in 2013, though no formal attestation was required as an "emerging growth company."
- Liquidity: As of December 31, 2013, the company had $13.5 million in cash and $6.0 million in available borrowing capacity under its term loan facility. Management believes this is sufficient for operations for at least the next 12 months.
Key Facts for Investor Verification
- Tax Benefit Impact: Verify the sustainability of earnings by analyzing the $21.8 million one-time tax benefit included in 2013 GAAP net income; Adjusted Net Income of $3.6 million is a more representative metric of operational performance.
- Competitive Bidding Exposure: Assess the long-term revenue impact of being excluded from 17 Medicare competitive bidding areas and the potential for further exclusions or rate reductions in future rounds.
- Reimbursement Dependency: Confirm the stability of the 41% of revenue derived from rentals, which relies heavily on Medicare and private insurance reimbursement rates that are subject to regulatory pressure.
- Debt Covenants: Review the terms of the $10.6 million debt facility with Comerica Bank, specifically the liquidity, debt service, and leverage ratio covenants, to ensure continued compliance.
- Internal Control Remediation: Monitor future filings to confirm that the remediation of internal control weaknesses remains effective and that no new material weaknesses are identified.